Back to journals
Academic JournalOpen Access

Frontiers in Psychiatry

84 Papers Indexed in Blossom

Data updated

Research Footprint

Frontiers in Psychiatry has 84 tracked papers indexed in Blossom (2018–2026) from 455 authors, most often covering Psilocybin, MDMA and Ketamine, across Anxiety Disorders, Depressive Disorders and PTSD.

Published Papers

Open Accessindividual

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

This qualitative study (n=14) explored how people with methamphetamine use disorder experienced ketamine-assisted psychotherapy and found that it was generally acceptable in a supportive setting. Participants described ketamine as creating a temporary state of reduced emotional and mental reactivity that seemed to help them engage with therapy, but changes in methamphetamine use were variable and depended on ongoing support and motivation.

Published
Journal
Frontiers in Psychiatry
Authors
Fletcher, K., Ezard, N., Siefried, K. J., van der Helder, S., Freestone, J., Brett, J., May, R., Acheson, L., Clifford, B.
Open Accessindividual

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins

This observational case study of identical twins found that repeated low doses of psilocybin in one twin with severe obsessive-compulsive disorder (OCD) were linked to lower perceived symptom severity and better emotional well-being. However, the affected twin still showed impaired cognitive flexibility compared with the unaffected twin.

Published
Journal
Frontiers in Psychiatry
Authors
Drange, S., Cohen, J., Johansen, S. S., Dunkley, B., Palner, M.
Open Accessindividual

Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes

This qualitative study (n=7) interviewed Swiss therapists about psychedelic-assisted therapy and found they saw psychedelics as working alongside psychotherapy rather than replacing it. Therapists described a synergy that could strengthen trust, depth and meaningful therapeutic experiences within long-term treatment.

Published
Journal
Frontiers in Psychiatry
Authors
Stellmacher, J., Schmidt, C., Aicher, H. D., Eichel, K., Brakemeier, E. L., Herwig, U.
Open Accessindividual

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization

This descriptive analysis of statewide data from Oregon’s regulated psilocybin services in 2025 found 5,935 clients in 5,375 sessions, mostly midlife adults, with substantial use by women and LGBTQ+ people but limited racial diversity. Acute behavioural and medical adverse events were rare, while many clients came from outside Oregon.

Published
Journal
Frontiers in Psychiatry
Authors
Yu, F., Tafur, J., Moreno, F., Dahmer, S.
Open Accessindividual

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Qualitative interviews with 12 participants from a randomized, placebo‑controlled single‑dose psilocybin trial for treatment‑refractory OCD showed that set and setting strongly shaped acute (often partial) perceptual, emotional and metacognitive experiences, which were followed by post‑dosing changes in OCD symptoms, perceptions and behavioural/metacognitive processes. These changes mapped onto putative mechanisms of ERP and ACT, suggesting hypotheses for further study and potential value in integrating psilocybin with structured psychotherapy for OCD.

Published
Journal
Frontiers in Psychiatry
Authors
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., Kelmendi, B.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.

Quick Facts

Papers Indexed
84
h-Index
134
Open Access
Yes
Publisher
Frontiers Media
Country
Switzerland
Website
Visit